

CLEARBRIDGE HEALTH LIMITED
(Company Registration No.: 201001436C)
(Incorporated in the Republic of Singapore)

**CORRIGENDUM TO THE
COMPANY'S ANNOUNCEMENT ON 7 OCTOBER 2022**

The board of directors (the "**Board**") of Clearbridge Health Limited (the "**Company**" or "**CBH**" and together with its subsidiaries, the "**CBH Group**") refers to the Company's announcement released on SGXNet on 7 October 2022 relating to the disposal of CBMA and SAM Labs (the "**Announcement**") and its responses in its announcements released on 17 October 2022 and 26 October 2022 to the queries by SGX RegCo. Unless otherwise defined, capitalised terms used in this announcement shall have the same meaning as ascribed to them in the Announcement.

The Board refers to paragraph 9 of the Announcement and wishes to announce that it has been informed recently by Mr. Yee Pinh Jeremy that his spouse holds an interest of 1.23% in the Purchaser ("**Relevant Interest**"). Accordingly, paragraph 9 of the Announcement should be read as follows (with the corrections being underlined for ease of reference):

"Our Independent Director, Mr. Mark Ryan, has an interest of 1.2% in the Purchaser and, consequently, he has abstained from all deliberations, discussions, recommendations and approval relating to the Disposal. Mr. Yee Pinh Jeremy's spouse has an interest of 1.23% in the Purchaser. Notwithstanding this, as this is not held by Mr. Yee Pinh Jeremy and does not constitute a personal material interest, he had not abstained from the deliberations, discussions, recommendations and approvals relating to the Disposal. Save as set out in this paragraph and for their respective shareholding interests in CBH, none of the other Directors or controlling shareholders of CBH or their associates have any interest, direct or indirect, in the Disposal."

The Relevant Interest was not earlier disclosed due to an oversight as such interest was acquired several years ago as part of the personal investments of Mr. Yee Pinh Jeremy's spouse and is not material. The Board, having considered the declarations made by Mr. Yee Pinh Jeremy and the materiality of the interest in the Purchaser held by his spouse, is of the view that this does not constitute a personal material interest of Mr. Yee Pinh Jeremy which requires him to abstain from voting on the Disposal in accordance with the constitution of the Company (which is compliant with paragraph 9(e) of Appendix 4C of the Catalyst Rules). The Board further confirms that the approval from the Board (with the abstention of Mr. Mark Ryan) to undertake the Disposal was unanimous and would have been passed regardless of Mr. Yee Pinh Jeremy's vote for or against the Disposal.

As set out in the Company's responses in its announcement on 17 October 2022, the Purchaser's controlling shareholders and directors (save for Dina Kumara Dinata who, as far as the Directors are aware, is a management staff of the Purchaser) were then and are business contacts of CBH's management. In particular, to the best of the Board's knowledge, Johan James Luhur, Wong Chi Wai Roy and Turodrique Fuad are also shareholders of CBH, holding less than 0.02%, less than 2.0% and less than 0.1% in CBH respectively. Subsequently, the Purchaser became a customer of the CBH Group in 2020, purchasing COVID-19 test kits and other healthcare and wellness products from the CBH Group to distribute in Indonesia.

Save as disclosed herein, none of Mr. Mark Ryan, Mr. Yee Pinh Jeremy or any of their respective associates is a substantial shareholder in any of the Company, the Purchaser or any subsidiaries of the Purchaser, and neither do they have any interest, direct or indirect, in the the Disposal.

Shareholders and potential investors of CBH are advised to exercise caution when dealing in the securities of CBH. Persons who are in doubt as to the action they should take should consult their stockbrokers, bank managers, solicitors or other professional advisers.

BY ORDER OF THE BOARD

Andrew John Lord
Lead Independent Director

15 December 2022

*This announcement has been prepared by CBH and has been reviewed by CBH's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the Catalist Rules. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*